

23 December 2019

EFPIA Japan

Thorsten Pöhl to become new chairman of EFPIA Japan

TOKYO—23 December 2019— EFPIA Japan announced today that Thorsten Pöhl (President and Representative Director, Boehringer Ingelheim Japan, Inc.) has been appointed the new chairman of EFPIA Japan, effective 1 January 2020.

Heike Prinz (President and Representative Director, Bayer Yakuhin, Ltd.), who continues in her current position as vice chairman, and Kazunari Tsunaba (President, Novartis Pharma K.K.), who has been newly appointed vice chairman, will support Thorsten Pöhl in his new role.

“I appreciate the trust that I have been given to lead EFPIA Japan in these challenging times,” says Thorsten Pöhl. “It is our foremost objective to bring innovative treatments and breakthrough therapies to the Japanese patient. We will continue to work together with all stakeholders to achieve this in all therapeutic areas as agilely as possible for the Japanese patients in need.”

EFPIA Japan Board Members as of 1 January 2020

Chairman	Thorsten Pöhl (Nippon Boehringer Ingelheim Japan, Co., Ltd.)	New
Vice Chairmen	Heike Prinz (Bayer Yakuhin, Ltd.)	
	Kazunari Tsunaba (Novartis Pharma K.K.),	New
Directors	Ole Mølskov Bech (Novo Nordisk Pharma Ltd.)	
	Stefan Woxström (AstraZeneca K.K.)	
	Paul Lirette (GlaxoSmithKline K.K.)	
	Takahiko Iwaya (Sanofi K.K.)	New
	Alexandere De Muralt (Merck Biopharma Co., Ltd.)	New
	Kanako Kikuchi (UCB Japan Co., Ltd.)	
Director General	Yoshitada Kimura (EFPIA Japan / Novo Nordisk Pharma Ltd.)	

About EFPIA Japan:

Established in April 2002, EFPIA Japan represents 23 R&D-based European pharmaceutical companies operating in Japan. In 2018, combined sales from the member companies accounted for roughly 23% of the pharmaceutical market in Japan. The mission of EFPIA Japan is to “Contribute to healthcare and patients in Japan through the early introduction of innovative medicines and vaccines”. EFPIA Japan aims to strengthen dialogue with decision-makers in order to improve Japanese healthcare for all.

About EFPIA (European Federation of Pharmaceutical Industries and Associations):

EFPIA, EFPIA Japan’s partner organisation, is headquartered in Brussels and represents the pharmaceutical industry operating in Europe. Through its direct membership of 36 national associations and 39 leading pharmaceutical companies, EFPIA provides the voice of 1,900 companies committed to researching, developing and bringing new medicines to improve health and quality of life around the world.

For more information please visit:

<http://efpia.jp/> (EFPIA Japan)

<http://www.efpia.eu> (EFPIA)

Contact:

EFPIA Japan Office

2-1-1 Marunouchi, Chiyoda-ku, Tokyo 100-0005

Phone: 03-6266-1354

Email: info@efpia.jp

Thorsten Pöhl profile



Current position:

President and Representative Director of Boehringer Ingelheim Japan, Inc.

Chairman and Representative Director of the following companies:

- Nippon Boehringer Ingelheim Co., Ltd.
- Boehringer Ingelheim Animal Health Japan Co., Ltd.
- Boehringer Ingelheim Seiyaku Co., Ltd.

Vice Chair of European Federation of Pharmaceutical Industries and Associations, Japan (EFPIA Japan)

.

Professional Experience

May 2016 President and Representative Director of Boehringer Ingelheim Japan, Inc.

Chairman and Representative Director of the following companies:

- Nippon Boehringer Ingelheim Co., Ltd.
- SSP Co., Ltd. (until December 2016)
- Boehringer Ingelheim Vetmedica Japan Co., Ltd.
- Boehringer Ingelheim Seiyaku Co., Ltd.

2013 President and CEO Boehringer Ingelheim España

2010 Senior Corporate Vice president, Talent Management, Boehringer Ingelheim GmbH

2008 President and CEO Boehringer Ingelheim Mexico Promeco, S.A. de C.V.

2005 President and CEO Boehringer Ingelheim Norway KS

2001 President and CEO Boehringer Ingelheim del Ecuador Cia. Ltda.

1993 Joined Boehringer Ingelheim GmbH